Alkermes (ALKS) Shares Outstanding (2010 - 2026)
Alkermes' (ALKS) quarterly Shares Outstanding (Entity) came in at $167.5 million in Q2 2026, up 1.51% year-over-year from $165.1 million in Q2 2025, and up 0.65% quarter-over-quarter from $166.5 million in Q1 2026.
Analysis
Alkermes (ALKS) Shares Outstanding (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $167.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 1.51% year-over-year to $167.5 million in Q2 2026; TTM through Jun 2026 was $167.5 million, a 1.51% increase from a year earlier, with the FY2025 full-year figure at $165.6 million, up 2.11% from the prior year.
- Shares Outstanding (Entity) was $167.5 million for Q2 2026 at Alkermes, up from $166.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $169.2 million in Q1 2024 and troughed at $161.8 million in Q3 2024.
- A 5-year average of $165.3 million and a median of $165.4 million in 2025 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) declined 2.96% in 2024 and climbed 2.11% in 2025, its largest moves.
- Over 5 years, Shares Outstanding (Entity) stood at $164.4 million in 2022, then rose by 1.58% to $167.0 million in 2023, then dropped by 2.88% to $162.2 million in 2024, then advanced by 2.11% to $165.6 million in 2025, then increased by 1.17% to $167.5 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $167.5 million (Q2 2026), $166.5 million (Q1 2026), and $165.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.82 Bn | 624.06 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 440.98 Bn | 434.41 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 364.65 Bn | 357.51 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 266.52 Bn | 258.83 Bn | 11.24 Bn | 1.94 Bn |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Sanofi | 52.51 Bn | 45.13 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 44.17 Bn | 44.17 Bn | - | 210.89 Mn |
| 8 | Incyte | 25.25 Bn | 20.71 Bn | 1.57 Bn | 200.38 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 42.60 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn | 167.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 167.03 Mn |
| Mar 31, 2026 | 166.20 Mn |
| Dec 31, 2025 | 164.70 Mn |
| Sep 30, 2025 | 165.09 Mn |
| Jun 30, 2025 | 164.96 Mn |
| Mar 31, 2025 | 163.41 Mn |
| Dec 31, 2024 | 165.39 Mn |
| Sep 30, 2024 | 163.37 Mn |
| Jun 30, 2024 | 168.32 Mn |
| Mar 31, 2024 | 167.98 Mn |
| Dec 31, 2023 | 166.22 Mn |
| Sep 30, 2023 | 166.61 Mn |
| Jun 30, 2023 | 166.28 Mn |
| Mar 31, 2023 | 165.09 Mn |
| Dec 31, 2022 | 163.54 Mn |
| Sep 30, 2022 | 164.28 Mn |
| Jun 30, 2022 | 163.84 Mn |
| Mar 31, 2022 | 162.48 Mn |
| Dec 31, 2021 | 160.94 Mn |
| Sep 30, 2021 | 161.46 Mn |